loading page

Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas
  • +9
  • Sean Mahase,
  • Michelle Roytman,
  • Diana Roth O’Brien,
  • Jana Ivanidze,
  • Theodore Schwartz,
  • Susan Pannullo,
  • Rohan Ramakrishna,
  • Rajiv Magge,
  • Nicholas Williams,
  • Howard Fine,
  • Gloria Chiang,
  • Jonathan Knisely
Sean Mahase
Penn State Hershey Cancer Institute

Corresponding Author:smahase1@gmail.com

Author Profile
Michelle Roytman
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Diana Roth O’Brien
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Jana Ivanidze
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Theodore Schwartz
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Susan Pannullo
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Rohan Ramakrishna
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Rajiv Magge
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Nicholas Williams
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Howard Fine
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Gloria Chiang
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile
Jonathan Knisely
NewYork-Presbyterian Weill Cornell Medical Center
Author Profile

Abstract

Background: Clinical trials evaluating immune checkpoint inhibition (ICI) in recurrent high-grade gliomas (rHGG) report 7-20% 6-month progression-free survival (PFS), while re-irradiation demonstrates 28%-39% 6-month PFS. Aims: We evaluate outcomes of patients treated with ICI and concurrent re-irradiation utilizing stereotactic body radiotherapy / fractionated stereotactic radiosurgery (SBRT) compared to ICI monotherapy. Methods and Results: Patients >18-years-old with rHGG (WHO grade III and IV) receiving ICI+SBRT or ICI monotherapy between 1/1/16-1/1/19 were included. Adverse events, 6-month PFS and overall survival (OS) were assessed. Log-rank tests were used to evaluate PFS and OS. Histogram analyses of apparent diffusion coefficient maps and dynamic contrast-enhanced magnetic resonance perfusion metrics were performed. Twenty-one patients with rHGG (ICI+SBRT: 16; ICI: 5) were included. The ICI+SBRT and ICI groups received a mean 7.25 and 6.2 ICI cycles, respectively. There were five grade 1, one grade 2 and no grade 3-5 AEs in the ICI+SBRT group, and four grade 1 and no grade 2-5 AEs in the ICI group. Median PFS was 2.85 and 1 month for the ICI+SBRT and ICI groups; median OS was 7 and 6 months among ICI+SBRT and ICI groups, respectively. There were significant differences in pre- and post-treatment tumor volume in the cohort (12.35 vs. 20.51; p=0.03), but not between treatment groups. Conclusions: In this heavily pretreated cohort, ICI with re-irradiation utilizing SBRT was well tolerated. Prospective studies are warranted to evaluate potential therapeutic benefits to re-irradiation with ICI+SBRT in rHGG.
16 Nov 2022Submitted to Cancer Reports
18 Nov 2022Submission Checks Completed
18 Nov 2022Assigned to Editor
18 Nov 2022Review(s) Completed, Editorial Evaluation Pending
25 Nov 2022Reviewer(s) Assigned
12 Dec 2022Editorial Decision: Revise Major
16 Dec 20221st Revision Received
17 Dec 2022Submission Checks Completed
17 Dec 2022Assigned to Editor
17 Dec 2022Review(s) Completed, Editorial Evaluation Pending
19 Dec 2022Reviewer(s) Assigned
21 Jan 2023Editorial Decision: Accept